A potent and selective second generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology
Route of Administration
Mode of Action
SPI-014 binds to phosphates and forms an insoluable lanthanum phosphate complex which is expected to reduce serum phosphate levels in ESRD patients.
More on SPI-014
Scanning Electron Micrograph (SEM) of SPI-014
Chronic Kidney Disease
According to the National Kidney Foundation, there are an estimated 26 million adults suffering from CKD in the US. Of these CKD patients, approximately 400,000 patients are at stage 4 and approximately 660,000 are at Stage 5 (ESRD). The incidence of ESRD is increasing at approximately 6% per year. Approximately 70% of ESRD patients have hyperphosphatemia.
In 2010, sales of phosphate binding agents are expected to increase to over $1B.